Key Drivers
- Strong margins
- High leverage
- Solid FCF
AIAI Summary
GE HealthCare's strategic pivot from cyclical capital equipment toward higher‑margin, recurring diagnostics, software/fleet services, and radiopharma reframes it as a hardware-plus-software platform whose valuation upside hinges concretely on measurable ARR growth from Intelerad and clear margin recovery (tariff reversals and sourcing wins). Monitor quarterly ARR/recurring revenue metrics, Intelerad integration milestones (cross-sell conversion, churn, and cash synergies), and any goodwill impairment triggers—failure on these would materially compress value given elevated leverage and tariff-driven margin volatility.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •High leverage
- •Solid FCF
GE HealthCare delivers strong margins, ROE and free cash flow but carries elevated leverage and significant intangible goodwill with only moderate liquidity and asset turnover.
Price Behavior
Key Price Behavior Insights:
- •Rapid decline
- •Support testing
- •Nearby resistance
GE HealthCare is in a clear short-term downtrend, falling roughly 17% over the last month and testing short-term support near $70–$72 while prior resistance sits around $80–$86.
~17% drop from $84.23 to $69.65 over the last month, raising volatility risk
Sentiment & News
Key News Insights:
- •Intelerad acquisition
- •View FDA clearance
- •UCSF alliance
GE HealthCare is accelerating a cloud-first, AI-driven imaging strategy—anchored by the $2.3B Intelerad deal and FDA clearance for its cloud-native View viewer—while strengthening partnerships and governance amid mixed investor activity.
The moves should boost recurring software revenue visibility and long-term growth positioning, but mixed institutional flows and technical weakness may sustain near-term stock volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings